Reversed-phase liquid chromatography method to determine COL-3, a matrix metalloproteinase inhibitor, in biological samples

Li, Jing; Huynh, Hung; Chan, Eli

doi:10.1016/j.jchromb.2003.10.066

Cited by 3 publications

(9 citation statements)

References 14 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,1,3,5,7,9,11,24,30,35, and 48 h after drug administration. A corresponding volume of 0.9% saline solution was injected through the femoral vein cannula to maintain a constant blood volume.…”

Section: Pharmacokinetic Studiesmentioning

confidence: 99%

“…The samples were thoroughly mixed and equilibrated at 37-C in a shaking water bath for 1 h; after that, each sample was transferred to a Microcon centrifugal filter device (Microcon YM-3) and centrifuged at 3,000 Â g at 37-C for 25 min. About 150 mL of ultrafiltrate was obtained, and an aliquot of 20 mL was subject to a validated HPLC method (24) to determine the unbound drug concentration.…”

Section: Rat Plasma Protein Binding Assaymentioning

confidence: 99%

See 1 more Smart Citation

Alteration of the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, Due to Acute Gastrointestinal Toxicity of Doxorubicin

Zhou

Huynh

et al. 2005

Pharm Res

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Pharmacokinetic Studiesmentioning

confidence: 99%

Section: Rat Plasma Protein Binding Assaymentioning

confidence: 99%

Alteration of the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, Due to Acute Gastrointestinal Toxicity of Doxorubicin

Zhou

Huynh

et al. 2005

Pharm Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Urine and feces were collected up to 48 h after dosing, and stored at -20°C until analysis. COL-3 in urine and feces were quantitated by a validated reversed-phase high-performance liquid chromatographic method with ultraviolet (UV) detector (11). The total of unchanged COL-3 and its glucuronide conjugate in rat urine was determined as previously described (9).…”

Section: Urinary and Fecal Excretionmentioning

confidence: 99%

“…The serum concentrations of COL-3 were determined using the validated HPLC method (11). The whole blood concentrations of COL-3 were measured using the same HPLC system with modified sample pretreatment.…”

Section: Erythrocyte Partitioningmentioning

confidence: 99%

“…The nonspecific adsorption of COL-3 to the Microcon filter device was examined with 5-50 g/ml of COL-3 in phosphate buffer (pH 7.4). The concentrations of COL-3 in the pre-and postcentrifuged phosphate buffer were determined by HPLC (11). The extent of nonspecific binding of COL-3 to the Microcon device was less than 2%.…”

Section: Rat/human Plasma Protein Bindingmentioning

confidence: 99%

See 1 more Smart Citation

Significant Intestinal Excretion, One Source of Variability in Pharmacokinetics of COL-3, a Chemically Modified Tetracycline

Zhou

Huynh

et al. 2005

Pharm Res

Self Cite

View full text Add to dashboard Cite

show abstract

Matrix Metalloproteinase Inhibitors: A Review on Bioanalytical Methods, Pharmacokinetics and Metabolism

Wang

Li²,

Adams³

et al. 2011

CDM

View full text Add to dashboard Cite

Enzymes are major drug targets in drug discovery and development processes in the pharmaceutical and biotechnology industry. A recent survey found that nearly half of all the marketed small-molecule drugs are inhibitors of enzymes. Matrix metalloproteinases (MMPs) are a family of 28 enzymes capable of degrading the constituents of the extracellular matrix (ECM) and the basement-membrane. MMPs play an essential role in several normal physiological processes including growth, wound healing and tissue repair. Over-expression and activation of MMPs has been linked to a range of diseases which include osteoarthritis, tumor metastasis, angiogenesis and cardiovascular diseases. The development of MMP inhibitors as therapeutic agents has kept an important place in drug discovery. Therefore, there is also an increasing need for robust analytical methods for evaluation of inhibitory potency and for the analysis of MMP inhibitors and their metabolites which can even play a more significant role than the parent drug. Modern analytical techniques and hyphenated instrumentations such as liquid chromatography-mass spectrometry with a function of structure elucidation can provide a profound insight into the research of MMP inhibitors and also serve as a complementary method to zymographic techniques for the analysis of biological samples. This review mainly summarizes bioanalytical methods, pharmacokinetics and related metabolites of MMP inhibitors over the last 12 years.

show abstract

Reversed-phase liquid chromatography method to determine COL-3, a matrix metalloproteinase inhibitor, in biological samples

Cited by 3 publications

References 14 publications

Alteration of the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, Due to Acute Gastrointestinal Toxicity of Doxorubicin

Alteration of the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, Due to Acute Gastrointestinal Toxicity of Doxorubicin

Significant Intestinal Excretion, One Source of Variability in Pharmacokinetics of COL-3, a Chemically Modified Tetracycline

Matrix Metalloproteinase Inhibitors: A Review on Bioanalytical Methods, Pharmacokinetics and Metabolism

Contact Info

Product

Resources

About